This study is not yet accepting patients
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at San Diego, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Alexander Kim
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSD
- Alexander Kim
Assistant Clinical Professor, Medicine. Authored (or co-authored) 5 research publications.
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Shire
- ID
- NCT04444895
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated